Moberg Pharma AB (publ)

Research Moberg Pharma AB (publ) (MB8) on Bullrun: market cap EUR 40.72M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerMB8
• ExchangeF
• CountrySweden
• SectorHealthcare
• IndustryDrug Manufacturers - Specialty & Generic
• CurrencyEUR
• Market capEUR 40.72M
• Financial periodFY2024
• RevenueSEK 9.81M
• Net income-SEK 255.11M
• Gross margin64.4%

Valuation Snapshot

latest market cap is EUR 40.72M.

About Moberg Pharma AB (publ)

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. It has license agreement with Karo Healthcare for distribution in European market. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.

Frequently asked questions

What is Moberg Pharma AB (publ)'s market cap?

Moberg Pharma AB (publ)'s market capitalization is EUR 40.72M.

What does Moberg Pharma AB (publ) do?

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand.